The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
(TBC) | selinexor | Multiple myeloma | Active | |||
Abecma | idecabtagene vicleucel | Multiple myeloma | Do not reimburse | Complete | ||
Abilify | Aripiprazole | Schizophrenia | Do not list | Complete | ||
Abilify | Aripiprazole | Depression, Major Depressive Disorder | Do not list | Complete | ||
Abilify | Aripiprazole | Schizophrenia and related psychotic disorders | List with clinical criteria and/or conditions | Complete | ||
Abilify Maintena | Aripiprazole | Schizophrenia | List with criteria/condition | Complete | ||
Abstral | Fentanyl citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
Aclasta | Zoledronic acid | Osteoporosis | List with clinical criteria and/or conditions | Complete | ||
Aclasta | Zoledronic acid | Osteoporosis, postmenopausal women | Do not list | Complete | ||
Actemra | Tocilizumab | Arthritis, juvenile idiopathic | List with clinical criteria and/or conditions | Complete |